The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDeltex Medical Regulatory News (DEMG)

Share Price Information for Deltex Medical (DEMG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.12
Bid: 0.11
Ask: 0.13
Change: -0.005 (-4.00%)
Spread: 0.02 (18.182%)
Open: 0.13
High: 0.12
Low: 0.11
Prev. Close: 0.125
DEMG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of Retail Offer

24 Jul 2023 07:00

RNS Number : 8804G
Deltex Medical Group PLC
24 July 2023
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, OR INTO OR WITHIN THE UNITED STATES, AUSTRALIA, NEW ZEALAND, CANADA, SOUTH AFRICA OR JAPAN, OR ANY MEMBER STATE OF THE EEA, OR ANY OTHER JURISDICTION WHERE, OR TO ANY OTHER PERSON TO WHOM, TO DO SO MIGHT CONSTITUTE A VIOLATION OR BREACH OF ANY APPLICABLE LAW OR REGULATION. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.

 

THE COMMUNICATION OF THIS ANNOUNCEMENT AND ANY OTHER DOCUMENTS OR MATERIALS RELATING TO THE RETAIL OFFER AS A FINANCIAL PROMOTION IS ONLY BEING MADE TO, AND MAY ONLY BE ACTED UPON BY, THOSE PERSONS IN THE UNITED KINGDOM FALLING WITHIN ARTICLE 43 OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005, AS AMENDED (WHICH INCLUDES AN EXISTING MEMBER OF DELTEX MEDICAL GROUP PLC). ANY INVESTMENT OR INVESTMENT ACTIVITY TO WHICH THIS ANNOUNCEMENT RELATES IS AVAILABLE ONLY TO SUCH PERSONS AND WILL BE ENGAGED IN ONLY WITH SUCH PERSONS. THIS ANNOUNCEMENT IS FOR INFORMATIONAL PURPOSES ONLY, AND DOES NOT CONSTITUTE OR FORM PART OF ANY OFFER OR INVITATION TO SELL OR ISSUE, OR ANY SOLICITATION OF AN OFFER TO PURCHASE OR SUBSCRIBE FOR, ANY SECURITIES OF DELTEX MEDICAL GROUP PLC.

 

The information contained within this announcement was deemed by the Company to constitute inside information as stipulated under the UK Market Abuse Regulation

 

24 July 2023

 

Deltex Medical Group plc

("Deltex Medical Group" or the "Company")

 

Result of Retail Offer

 

On 14 July 2023, Deltex Medical Group (AIM: DEMG) announced that it has conditionally raised approximately £1.67 million pursuant to a Placing and Subscription and launched a Retail Offer on the REX Platform to existing shareholders. The Retail Offer closed at 5.00 p.m. on Friday, 21 July 2023 and has conditionally raised gross proceeds of £221,258.54 at the Issue Price. As a result, the Company has conditionally raised a total of approximately £1.89 million pursuant to the Placing, Subscription and Retail Offer (together, the "Fundraise").

 

The Retail Offer will result in the issue of a total of 110,629,270 Retail Offer Shares. In total, 943,629,270 Fundraising Shares will be issued pursuant to the Fundraise.

 

The Retail Offer, Placing and Subscription remain subject to, inter alia, the passing of certain Resolutions at a General Meeting of the Company on 1 August 2023, as well as the resumption of trading on AIM of the Company's Ordinary Shares and Admission. Application will be made to the London Stock Exchange for the New Ordinary Shares (including the Fundraising Shares, the Fee Shares and the Loan Conversion Shares) to be admitted to trading on AIM and subject to the passing of the Resolutions, it is expected that Admission will become effective and dealings in the New Ordinary Shares (including the Fundraising Shares) will commence on AIM at 8.00 a.m. on 2 August 2023. 

 

Terms used but not defined in this announcement have the same meaning as set out in the Company's announcement released at 18:01 on 14 July 2023.

 

Enquiries: 

 

For further information, please contact:

 

Deltex Medical Group plc

01243 774 837

Nigel Keen, Chairman

investorinfo@Deltexmedical.com

Andy Mears, Chief Executive

Natalie Wettler, Group Finance Director

Allenby Capital Limited - Nominated Adviser & Broker

020 3328 5656

Jeremy Porter / Vivek Bhardwaj (Corporate Finance)

info@allenbycapital.com

Tony Quirke / Stefano Aquilino (Sales & Corporate Broking)

 

The Company's LEI is 213800XN34P6LI8J6M39. 

 

This announcement should be read in its entirety. In particular, the information in the "Important Notices" section of the announcement should be read and understood.

 

Important Notices

 

The content of this announcement has been prepared by and is the sole responsibility of the Company.

 

This announcement and the information contained herein is not for release, publication or distribution, directly or indirectly, in whole or in part, in or into or from the United States (including its territories and possessions, any state of the United States and the District of Columbia (the "United States" or "US")), Australia, Canada, New Zealand, Japan, the Republic of South Africa, any member state of the EEA or any other jurisdiction where to do so might constitute a violation of the relevant laws or regulations of such jurisdiction.

 

The Retail Offer Shares have not been and will not be registered under the US Securities Act of 1933, as amended (the "US Securities Act") or under the applicable state securities laws of the United States and may not be offered or sold directly or indirectly in or into the United States. No public oering of the Retail Offer Shares is being made in the United States. The Retail Offer Shares are being oered and sold outside the United States in "oshore transactions", as dened in, and in compliance with, Regulation S under the US Securities Act. In addition, the Company has not been, and will not be, registered under the US Investment Company Act of 1940, as amended.

 

This announcement does not constitute an offer to sell or issue or a solicitation of an offer to buy or subscribe for Retail Offer Shares in the United States, Australia, Canada, New Zealand, Japan, the Republic of South Africa, any member state of the EEA or any other jurisdiction in which such offer or solicitation is or may be unlawful. No public offer of the securities referred to herein is being made in any such jurisdiction.

 

This announcement is not for publication or distribution, directly or indirectly, in or into the United States of America. This announcement is not an offer of securities for sale into the United States. The securities referred to herein have not been and will not be registered under the US Securities Act, and may not be offered or sold in the United States, except pursuant to an applicable exemption from registration. No public offering of securities is being made in the United States.

 

The distribution of this announcement may be restricted by law in certain jurisdictions and persons into whose possession any document or other information referred to herein comes should inform themselves about and observe any such restriction. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.

 

REX is a proprietary technology platform owned and operated by Peel Hunt LLP (registered address at 7th Floor, 100 Liverpool Street, London EC2M 2AT; FRN 530083). Peel Hunt LLP ("Peel Hunt") is authorised and regulated in the United Kingdom by the Financial Conduct Authority, is acting exclusively for the Company and for no-one else and will not regard any other person (whether or not a recipient of this announcement) as its client in relation to the Retail Offer and will not be responsible to anyone other than the Company for providing the protections afforded to its clients, nor for providing advice in connection with the Retail Offer, Admission and the other arrangements referred to in this announcement.

 

The value of Ordinary Shares and the income from them is not guaranteed and can fall as well as rise due to stock market movements. When you sell your investment, you may get back less than you originally invested. Figures refer to past performance and past performance is not a reliable indicator of future results. Returns may increase or decrease as a result of currency fluctuations.

 

Certain statements in this announcement are forward-looking statements which are based on the Company's expectations, intentions and projections regarding its future performance, anticipated events or trends and other matters that are not historical facts. These forward-looking statements, which may use words such as "aim", "anticipate", "believe", "intend", "estimate", "expect" and words of similar meaning, include all matters that are not historical facts. These forward-looking statements involve risks, assumptions and uncertainties that could cause the actual results of operations, financial condition, liquidity and dividend policy and the development of the industries in which the Company's businesses operate to differ materially from the impression created by the forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Given those risks and uncertainties, prospective investors are cautioned not to place undue reliance on forward-looking statements.

 

These forward-looking statements speak only as at the date of this announcement and cannot be relied upon as a guide to future performance. The Company and Peel Hunt expressly disclaim any obligation or undertaking to update or revise any forward-looking statements contained herein to reflect actual results or any change in the assumptions, conditions or circumstances on which any such statements are based unless required to do so by the Financial Conduct Authority, the London Stock Exchange or applicable law.

 

The information in this announcement is for background purposes only and does not purport to be full or complete. None of Peel Hunt or any of its affiliates, accepts any responsibility or liability whatsoever for, or makes any representation or warranty, express or implied, as to this announcement, including the truth, accuracy or completeness of the information in this announcement (or whether any information has been omitted from the announcement) or any other information relating to the Company or associated companies, whether written, oral or in a visual or electronic form, and howsoever transmitted or made available or for any loss howsoever arising from any use of the announcement or its contents or otherwise arising in connection therewith. Peel Hunt and its affiliates, accordingly disclaim all and any liability whether arising in tort, contract or otherwise which they might otherwise be found to have in respect of this announcement or its contents or otherwise arising in connection therewith.

 

Any indication in this announcement of the price at which the Ordinary Share have been bought or sold in the past cannot be relied upon as a guide to future performance. Persons needing advice should consult an independent financial adviser. No statement in this announcement is intended to be a profit forecast and no statement in this announcement should be interpreted to mean that earnings or target dividend per share of the Company for the current or future financial years would necessarily match or exceed the historical published earnings or dividends per share of the Company.

 

Neither the content of the Company's website (or any other website) nor the content of any website accessible from hyperlinks on the Company's website (or any other website) is incorporated into or forms part of this announcement. The Retail Offer Shares to be issued or sold pursuant to the Retail Offer will not be admitted to trading on any stock exchange other than the London Stock Exchange.

 

It is further noted that the Retail Offer is only open to investors in the United Kingdom who fall within Article 43 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (which includes an existing member of the Company).

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ROIUOSRRONUBUUR
Date   Source Headline
23rd Dec 201012:39 pmRNSGrant of Options
23rd Dec 201012:35 pmRNSAdditional Listing
16th Dec 20107:00 amRNSParis Hospital System Contract for CardioQ-ODMT
14th Dec 20103:52 pmRNSDirector/PDMR Shareholding
14th Dec 201010:43 amRNSHolding(s) in Company
14th Dec 20109:21 amRNSHolding(s) in Company
29th Nov 20101:04 pmRNSAdditional Listing
20th Oct 20103:01 pmRNSWorthing Hospital wins award (Replacement)
20th Oct 20107:00 amRNSWorthing Hospital wins award
13th Oct 20104:00 pmRNSDirector/PDMR Shareholding
13th Oct 20104:00 pmRNSDirector/PDMR Shareholding
6th Oct 20103:56 pmRNSNotification of Major Interest in Shares
4th Oct 20102:02 pmRNSPositive NICE draft guidance on CardioQ-ODM
20th Jul 20107:00 amRNSTrading Statement
25th Jun 20103:47 pmRNSDirectors' Shareholdings
25th Jun 20103:42 pmRNSGrant of Options
22nd Jun 20102:45 pmRNSDirector/PDMR Shareholding
8th Jun 20107:00 amRNSNICE
6th May 20109:18 amRNSUS Order
28th Apr 20101:23 pmRNSResult of AGM
28th Apr 201011:31 amRNSAGM Statement
31st Mar 20105:45 pmRNSAmendment - Director/PDMR Shareholding
31st Mar 20105:17 pmRNSDirector/PDMR Shareholding
31st Mar 20105:08 pmRNSAdditional Listing
29th Mar 20103:26 pmRNSAdditional Listing
24th Mar 20102:52 pmRNSHolding(s) in Company
24th Mar 20107:01 amRNSNon-Executive Directors' shareholdings
24th Mar 20107:00 amRNSGrant of Options
23rd Mar 20107:00 amRNSNew UK Government reports covering ODM
16th Mar 20107:00 amRNSPreliminary Results
28th Jan 20107:00 amRNSNew study verifies the value of CardioQ-ODMT
14th Jan 20101:13 pmRNSResults of NHS Study
13th Jan 20107:00 amRNSPre-Close Update
30th Dec 20097:02 amRNSAdditional Listing
30th Dec 20097:01 amRNSDirector/PDMR Shareholding
30th Dec 20097:00 amRNSGrant of options
30th Nov 20097:00 amRNSTotal Voting Rights
17th Nov 20097:00 amRNSODM recommended by international clinic
17th Nov 20097:00 amRNSNHS Trust wins award for implementation of ODM
16th Nov 200911:51 amRNSHolding(s) in Company
12th Nov 20094:24 pmRNSAdditional Listing
6th Nov 200911:52 amRNSHolding(s) in Company
3rd Nov 200910:04 amRNSHolding(s) in Company
3rd Nov 20097:00 amRNSDirector/PDMR Shareholding
30th Oct 200911:03 amRNSResult of Meeting
15th Oct 20097:01 amRNSCardioQ-ODM used as gold standard
15th Oct 20097:00 amRNSNHS National Technology Adoption Centre Update
14th Oct 20091:58 pmRNSConditional raising to raise ?2.0 million
21st Sep 200910:56 amRNSSpanish colorectal surgery update
14th Sep 200911:51 amRNSItalian Medical Study

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.